Rani Therapeutics Holdings, Inc. (RANI) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
7.87
↑+66% vs avg
5yr avg: 4.76
30Y Low1.9·High11.2
ROE
↓
-207.5%
↑-63% vs avg
5yr avg: -127.4%
30Y Low-207%·High-31%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RANI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Rani Therapeutics Holdings, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $23M | $39M | $85M | $141M | $319M | — | — |
| Enterprise Value | $49M | $65M | $109M | $144M | $202M | — | — |
| P/E Ratio → | -0.92 | — | — | — | — | — | — |
| P/S Ratio | 22.51 | 37.95 | — | — | 117.55 | — | — |
| P/B Ratio | 7.87 | 11.17 | 3.33 | 1.90 | 2.63 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RANI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 63.19 | — | — | 74.32 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
RANI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Rani Therapeutics Holdings, Inc. earns an operating margin of -5186.2%. A negative ROE of -207.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | — | 100.0% | 100.0% | 100.0% |
| Operating Margin | -5186.2% | -5186.2% | — | — | -1899.1% | -3581.0% | -2764.6% |
| Net Profit Margin | -2920.0% | -2920.0% | — | — | -306.6% | -3615.4% | -2716.8% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -207.5% | -207.5% | -68.3% | -31.3% | -202.5% | — | — |
| ROA | -63.5% | -63.5% | -40.9% | -26.3% | -8.2% | -32.6% | -115.5% |
| ROIC | -101.1% | -101.1% | -78.1% | -117.0% | -940.7% | — | — |
| ROCE | -159.9% | -159.9% | -86.3% | -56.5% | -52.7% | -35.3% | -138.6% |
RANI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $26M ($30M total debt minus $4M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 8.51 | 8.51 | 1.18 | 0.41 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 7.43 | 0.95 | 0.04 | -0.97 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -10.59 | -10.59 | -13.00 | -59.24 | -110.73 | -133.42 | -2706.50 |
RANI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.50x means Rani Therapeutics Holdings, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 20.96x to 1.50x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 1.50 | 1.50 | 6.36 | 20.96 | 45.30 | 14.12 | 4.84 |
| Quick Ratio | 1.50 | 1.50 | 6.36 | 20.96 | 45.30 | 14.12 | 4.84 |
| Cash Ratio | 1.39 | 1.39 | 6.08 | 20.45 | 44.49 | 13.76 | 4.73 |
| Asset Turnover | — | 0.03 | — | — | 0.02 | 0.01 | 0.04 |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 151.97 | — | — | — | 1358.87 | 93.21 |
RANI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Rani Therapeutics Holdings, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $28M | $26M | $24M | $20M | $19M | $19M |
Peer Comparison
Compare RANI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RANIYou | $23M | -0.9 | — | — | 100.0% | -5186.2% | -207.5% | -101.1% | — |
 LNTH | $6B | 27.3 | 15.0 | 17.1 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 NUVL | $8B | -18.0 | — | — | — | — | -36.7% | -32.5% | — |
 ARQT | $3B | -162.8 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 PRAX | $10B | -24.5 | — | — | — | — | -45.8% | -65.0% | — |
 CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
 TNGX | $3B | -26.5 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 INVA | $2B | 6.9 | 6.9 | 8.6 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 NKTR | $2B | -8.4 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 AVXL | $298M | -6.0 | — | — | — | — | -43.1% | — | — |
 MNKD | $1B | 176.0 | 29.1 | 79.4 | 82.5% | 11.1% | — | 21.6% | 9.3 |
| Healthcare Median | — | 21.9 | 14.2 | 18.5 | 64.3% | -5.0% | -34.0% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See RANI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RANI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RANI vs LNTH
Side-by-side business, growth, and profitability comparison vs Lantheus Holdings, Inc..
Start ComparisonRANI — Frequently Asked Questions
Quick answers to the most common questions about buying RANI stock.
What is Rani Therapeutics Holdings, Inc.'s P/E ratio?
Rani Therapeutics Holdings, Inc.'s current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
What is Rani Therapeutics Holdings, Inc.'s ROE?
Rani Therapeutics Holdings, Inc.'s return on equity (ROE) is -207.5%. The historical average is -127.4%.
Is RANI stock overvalued?
Based on historical data, Rani Therapeutics Holdings, Inc. is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Rani Therapeutics Holdings, Inc.'s profit margins?
Rani Therapeutics Holdings, Inc. has 100.0% gross margin and -5186.2% operating margin.